Back to search
Scientific Name: Dextropropoxyphene
Brand Name: Darvocet-N, Darvon
Company Owner: Xanodyne pharmaceutics inc, Heritage pharmaceuticals inc, Mk laboratories inc, Halsey drug co inc, Alra laboratories inc, Impax laboratories inc, Ivax pharmaceuticals inc sub teva pharmaceuticals usa, Mutual pharmaceutical co inc, Mylan pharmaceuticals inc, Nexgen pharma inc, Par pharmaceutical inc, Purepac pharmaceutical co, Private formulations inc, Roxane laboratories inc, Sandoz inc, Teva pharmaceuticals usa inc, Valeant pharmaceuticals international, Vintage pharmaceuticals inc, Watson laboratories inc, West ward pharmaceutical corp, Whiteworth towne paulsen inc, Warner chilcott div warner lambert co, Aaipharma llc
Mechanism Of Action Propoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS) . Propoxyphene primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as propoxyphene also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist) . This results in hyperpolarization and reduced neuronal excitability.
Description of the Drug: Dextropropoxyphene is an opioid analgesic used to treat mild to moderate pain.
Protein Data Bank: Not Available
Source: DrugBank Online – Retrieved 2023-01-23 from